A High Percentage of NSCLC With Germline <i>CHEK2</i> Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.

Zhang, Shannon S; Lee, Jessica K; Tukachinsky, Hanna; Schrock, Alexa B; Nagasaka, Misako; Ou, Sai-Hong Ignatius

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.

Zhang, Shannon S; Lee, Jessica K; Tukachinsky, Hanna; Schrock, Alexa B; Nagasaka, Misako; Ou, Sai-Hong Ignatius.

Afiliação

Zhang SS; Department of Medicine, University of California Irvine School of Medicine, Orange, California.
Lee JK; Foundation Medicine Inc., Cambridge, Massachusetts.
Tukachinsky H; Foundation Medicine Inc., Cambridge, Massachusetts.
Schrock AB; Foundation Medicine Inc., Cambridge, Massachusetts.
Nagasaka M; Department of Medicine, University of California Irvine School of Medicine, Orange, California.
Ou SI; Chao Family Comprehensive Cancer Center, Orange, California.

JTO Clin Res Rep ; 3(9): 100387, 2022 Sep.

Article em En | MEDLINE | ID: mdl-36061833

Palavras-chave

Actionable driver mutation; EGFR; Germline CHEK2 mutation; KRAS; NSCLC; Plasma genotyping; Tumor genotyping

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article